Cadonilimab and radiation for advanced cervical cancer without chemo
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two treatments: a drug called cadonilimab (a type of immunotherapy that helps your immune system fight cancer) and radiation therapy. It is for people with advanced cervical cancer who cannot receive the usual chemotherapy drug cisplatin, and aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with cervical cancer, specifically squamous cell or adenosquamous carcinoma (the two most common types).
- Your cancer is at an advanced stage (FIGO stage IB3 to IVA) or you cannot have surgery and need radiation therapy.
- You are generally well enough to get treatment (ECOG score 0-2) and are expected to live at least 6 more months.
- You cannot receive the usual chemotherapy drug cisplatin because of reasons like age (70+), kidney problems, heart issues, an allergy to platinum drugs, or you chose not to have chemo after discussing it with your doctor.
- You have not had prior treatment with immune checkpoint inhibitors (like PD-1 or PD-L1 blockers) and have no active infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding cadonilimab (an immune therapy) to standard radiation can improve treatment for locally advanced cervical cancer. It may help your immune system work better against the cancer while radiation shrinks it.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemoradiation for cervical cancer that has spread to a few other places in the body. It aims to see if this combination can help control the cancer better.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.